Association between the systemic immune‐inflammation index and outcomes among atrial fibrillation patients with diabetes undergoing radiofrequency catheter ablation
Clinical Cardiology · 2023-11 · 46 (11) · 1426-1433
DOI: 10.1002/clc.24116 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Cardiology, online erschienen am 08.08.2023. Verfasst von Zhihao Zhao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University, Xuzhou First People's Hospital, Xuzhou, China. Hauptthemen laut MEDLINE: Atrial Fibrillation, Diabetes Mellitus, Catheter Ablation. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Purpose
To investigate the relationship between the incidence of atrial fibrillation (AF) recurrence and the levels of the systemic immune‐inflammatory index (SII, platelet × neutrophil/lymphocyte ratio) in patients with AF and diabetes mellitus (DM) undergoing after radiofrequency catheter ablation (RFCA). Patients and Methods Preoperative SII levels were determined in AF patients with DM undergoing RFCA. Restricted cubic splines were used to determine the correlation between SII and the risk of AF recurrence. Multivariate‐adjusted logistic regression models were constructed to determine the relationship between SII levels and AF recurrence. The predictive value of the clinical model and combined with the SII index was estimated by the area under the receiver‑operating characteristic curve, net reclassification improvement (NRI), and integrated discrimination improvement (IDI).
Results
A total of 204 patients with AF and DM who underwent RFCA in our hospital were included. Seventy‐seven patients had AF recurred during a mean follow‐up of 20 months. Restricted cubic spline analysis showed that when SII ≥ 444.77 × 10 9 /L, there was a positive correlation with the incidence of AF recurrence. In addition, adding the SII to the predictive model for AF recurrence after RFCA in patients with DM and AF could contribute to an increase in C‐statistics (0.798 vs. 0.749, p = .034). After SII was incorporated into the clinical model, the comprehensive discrimination and net reclassification tended to improve (IDI and NRI > 0, p < .05).
Conclusion
SII was independently and positively associated with recurrence after the first catheter ablation in patients with DM and AF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, The Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University, Xuzhou First People's Hospital, Xuzhou, China.
- Department of Cardiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
- Department of Clinical Nutrition, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Zitieren
APA
Zhao, Z., Jiang, B., Zhang, F., Ma, R., Han, X., Li, C., Zhang, C., Wang, Z., & Yang, Y. (2023). Association between the systemic immune‐inflammation index and outcomes among atrial fibrillation patients with diabetes undergoing radiofrequency catheter ablation. Clinical Cardiology, 46(11), 1426-1433. https://doi.org/10.1002/clc.24116
Vancouver
Zhao Z, Jiang B, Zhang F, Ma R, Han X, Li C, et al. Association between the systemic immune‐inflammation index and outcomes among atrial fibrillation patients with diabetes undergoing radiofrequency catheter ablation. Clinical Cardiology. 2023;46(11):1426-1433. doi:10.1002/clc.24116
BibTeX
@article{Zhao2023,
author = {Zhao, Zhihao and Jiang, Baoping and Zhang, Fengyun and Ma, Ruicong and Han, Xiao and Li, Chengzong and Zhang, Chaoqun and Wang, Zhirong and Yang, Yu},
title = {Association between the systemic immune‐inflammation index and outcomes among atrial fibrillation patients with diabetes undergoing radiofrequency catheter ablation},
journal = {Clinical Cardiology},
year = {2023},
volume = {46},
number = {11},
pages = {1426--1433},
doi = {10.1002/clc.24116}
}
EUVIMED